Skip to main content

Membrane adsorption in vancomycin treatment is membrane type dependent in CVVHDF: dose correction is crucial

Kirwan et al. concluded that target attainment with acceptable trough vancomycin concentrations can be achieved early in treatment with a 2000 mg loading dose and maintenance dose of 750 mg 12 hourly for patients on continuous venovenous haemodiafiltration (CVVHDF) [1]. However, the Kirwan study was completed 7 years ago, using a polyarylethersulfone (PAES) which is well known to be a non-adsorptive membrane [1]. In current practice, more than 95% of treatments with the Prismaflex take place with the adsorptive acrylonitrile 69 surface treated (AN69-ST) [2, 3], which also absorbs significant amounts of vancomycin [2]. Accordingly, using a loading dose of 2000 mg and a maintenance dose of 750 mg/12 h in CVVHDF with the present day standard of practice, using a prismaflex with an AN69ST, could risk treatment failure [2]. In a recent study comparing adsorption of vancomycin in AN69ST versus Polysulphone (PS) (with similar specifications to non-adsorptive membranes such as PAES), there was a significant adsorption of roughly 200 mg in 2 h by AN69ST compared to PS [2]. In vitro, Tian studied vancomycin adsorption of AN69, polyamide, and PS membranes in a hemofiltration model [3]. Vancomycin (36 mg) was added to a volume of a blood-crystalloid (target concentration 50 mg/l) [3]. Adsorption, calculated by the fall in concentration over 120 min, in the 0.6-m2 AN69 filters was significantly greater (10.08 ± 2.26 mg) than in the 0.6-m2 polyamide (5.20 ± 1.82 mg) or in the 0.7-m2 PS (4.80 ± 2.40 mg) filters [3]. Theoretically, an AN69ST membrane could therefore irreversibly take up almost one third of the initial dose [3]. If proven in vivo, loading and maintenance vancomycin doses would have to be adapted accordingly [3]. Because we routinely apply continuous renal replacement therapy (CRRT) using the AN69 ST, we were able to retrospectively demonstrate that daily vancomycin maintenance doses close to 3,000 mg daily were needed during the first 3 treatment days [4]. Choi demonstrated that, within the first hour after changing the membrane, a striking decline in vancomycin trough concentration occurred, which necessitated a considerable increase in the continuous infusion dose [5].

In conclusion, the clinician should be aware of the specific adsorptive properties of the membrane used and dose accordingly. Both personalization of vancomycin dosing and therapeutic drug monitoring for these patients is essential to guide dose scheduling.

Availability of data and materials

Not applicable.

Abbreviations

CVVHDF:

Continuous venovenous haemodiafiltration

PAES:

Polyarylethersulfone

AN69-ST:

Acrylonitrile 69 surface treated

PS:

Polysulphone

CRRT:

Continuous renal replacement therapy

References

  1. Kirwan M, Munshi R, O’Keeffe H, et al. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF). Crit Care. 2021;25(1):443. https://doi.org/10.1186/s13054-021-03863-4.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Onichimowski D, Ziółkowski H, Nosek K, et al. Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies. J Artif Organs. 2020;23(2):163–70. https://doi.org/10.1007/s10047-019-01139-x.

    CAS  Article  PubMed  Google Scholar 

  3. Tian Q, Gomersall CD, Leung PP, et al. The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs. 2008;32:81–4.

    CAS  PubMed  Google Scholar 

  4. Honore PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59(2):99–106. https://doi.org/10.1097/MAT.0b013e3182816a75.

    CAS  Article  PubMed  Google Scholar 

  5. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268–82.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Affiliations

Authors

Contributions

PMH, SB, DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Patrick M. Honore.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare to have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Redant, S., Djimafo, P. et al. Membrane adsorption in vancomycin treatment is membrane type dependent in CVVHDF: dose correction is crucial. Crit Care 26, 117 (2022). https://doi.org/10.1186/s13054-022-03991-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-022-03991-5

Keywords

  • Vancomycin
  • Doses
  • PAES membrane
  • AN69ST membrane